Corneal endothelial deposits associated with rifabutin use

dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.contributorMcGill Univ
dc.creatorCoutinho, A. B.
dc.creatorCheema, D.
dc.creatorPereira, P. R.
dc.creatorFilho, JPS
dc.creatorBurnier, M. N.
dc.date.accessioned2016-01-24T12:37:46Z
dc.date.accessioned2022-10-07T20:39:18Z
dc.date.available2016-01-24T12:37:46Z
dc.date.available2022-10-07T20:39:18Z
dc.date.created2016-01-24T12:37:46Z
dc.date.issued2005-04-01
dc.identifierJournal of Ocular Pharmacology and Therapeutics. New Rochelle: Mary Ann Liebert Inc, v. 21, n. 2, p. 166-169, 2005.
dc.identifier1080-7683
dc.identifierhttp://repositorio.unifesp.br/handle/11600/28232
dc.identifier10.1089/jop.2005.21.166
dc.identifierWOS:000228731300009
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4020660
dc.description.abstractPurpose: the aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.Methods: Case series consisting of 3 patients treated with rifabutin were retrospectively studied. Two of the patients were infected with human immunodeficiency virus. A corneal and external disease specialist performed a complete ophthalmologic exam and obtained medical histories of the patients.Results: All cases developed corneal endothelial deposits after previous use of rifabutin. the deposits were bilateral, yellow-white colored, stellate, and mainly peripheral.Conclusions: in these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.
dc.languageeng
dc.publisherMary Ann Liebert Inc
dc.relationJournal of Ocular Pharmacology and Therapeutics
dc.rightsAcesso restrito
dc.titleCorneal endothelial deposits associated with rifabutin use
dc.typeArtigo


Este ítem pertenece a la siguiente institución